We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Chitosan-Coated Implants Can Prevent Infections

By HospiMedica staff writers
Posted on 25 Sep 2006
A new study has found that coating implants and implantable devices with chitosan--a sugar found in the cells of crabs and shrimps--can prevent implant infections.

Researchers from Montana State University (MSU, Bozeman, MT, USA) found that chitosan repelled bacteria and yeast, effectively preventing these microbes from forming biofilms--slimy, glue-like layers of infectious cells. More...
As a biomaterial, chitosan has a track record of non-toxicity, biocompatibility, ability to promote healing, and inherent antimicrobial properties. However, this is the first time its anti-biofilm activity has been described. The study was presented at the national meeting of the American Chemical Society, held in September 2006 in San Francisco (CA, USA).

Biofilms can arise on virtually any device implanted in the body, including mechanical heart valves, contact lens, artificial hips and knees, and breast implants. Once a biofilm-induced infection takes hold, it can be difficult to treat and often requires the surgical removal of the affected device. Biofilms are considered the leading cause of up to 65% of catheter-related bloodstream infections each year in the United States alone.

"Coating chitosan onto a surface seems to stop bacteria and yeast from colonizing that surface,” said lead author Philip Stewart, Ph.D., director of MSU's Center for Biofilm Engineering. "Chitosan almost acts like a bed of nails. If a microbe alights on it, the chitosan skewers it or causes it to leak. That might not kill microbes outright, but it certainly discourages them from establishing a foothold.”

Chitosan is derived from chitin, the main component of crustacean shells. It is sold commercially as a nutritional supplement. Chitosan is also used to staunch blood loss, as a thickener in cosmetics, as a flocculating agent in water treatment, and is also used in biomaterials.



Related Links:
Montana State University

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Open Stapler
PROXIMATE Linear Cutter
Mammo DR Retrofit Solution
DR Retrofit Mammography
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.